With these new launches, Mayoly is further strengthening its support for patients suffering from sensitive intestines.
Widely prescribed for the symptomatic treatment of functional intestinal disorders, particularly bloating, with METEOSPASMYL®, Mayoly is taking a new step forward in conquering the OTC market with DOLOSPASMYL®. DOLOSPASMYL is a non-reimbursable, over-the-counter medicine available in two pack sizes: 10 soft capsules, allowing new patients to try DOLOSPASMYL, and 30 capsules, meeting the needs of our loyal patients.


To further support patients, Mayoly is also expanding its range with DOLOCOLMYL®, a medical device designed to relieve the symptoms of irritable bowel syndrome: abdominal pain, bloating and transit disorders.

These two launches confirm Mayoly’s ambition to strengthen its expertise, visibility and growth in the field of gastroenterology.
Congratulations french team for the launch, big first step into OTC with Dolospamsyl and range extension with local innovation Dolocolmyl!